Eagle Pharmaceuticals, INC.: insider trades · United States · SEC (Form 4)

About Eagle Pharmaceuticals, INC.

Eagle Pharmaceuticals, Inc. (EGRX) is a U.S.-listed specialty pharmaceutical company traded on the NASDAQ in the United States. The company is headquartered in Woodcliff Lake, New Jersey, and was founded in January 2007 by Scott Tarriff, who remains closely associated with its origin story and strategic identity. Eagle’s business model has traditionally centered on developing, manufacturing, and commercializing injectable products, primarily through the FDA’s 505(b)(2) pathway. That framework allows the company to build differentiated products around existing therapies, reducing some of the development risk and time associated with fully novel drug programs. Eagle first established its reputation in critical care and oncology. Its commercial portfolio has included RYANODEX® (dantrolene injectable suspension), BENDEKA® and BELRAPZO® (bendamustine formulations), and PEMFEXY® (pemetrexed injection). In 2022, Eagle expanded materially into acute care through the acquisition of Acacia Pharma, adding BARHEMSYS® and BYFAVO® to the portfolio. That transaction broadened the company’s hospital-facing footprint into postoperative nausea and vomiting treatment and procedural sedation, complementing its existing oncology and critical care franchises. Eagle describes itself as a fully integrated pharmaceutical company with research and development, clinical, manufacturing, and commercial capabilities. From a competitive standpoint, Eagle operates as a focused specialty player rather than a broad large-cap pharmaceutical company. Its edge lies in hospital commercialization expertise, targeted clinical positioning, and the ability to improve established products through formulation and delivery innovation. The company’s products address niche or underserved needs in oncology, anesthesia, acute care, and critical care settings, where clinician adoption can be driven by practical advantages, differentiated labeling, or operational convenience. This specialization can support strong franchise economics when products achieve traction, although the model also remains exposed to reimbursement pressure, competition, and product concentration risk. Geographically, Eagle remains primarily U.S.-focused, though it has had some international commercial exposure in the past. Recent company updates show continued activity in 2025, including interim financial statement availability and a series of SEC Form 4 insider transaction filings, underscoring ongoing market scrutiny around ownership changes and management alignment. The company has also made portfolio adjustments and strategic announcements that suggest active capital and asset management. For investors, Eagle should be viewed as a U.S. NASDAQ-listed specialty pharma company with a hospital and oncology focus, a history of growth through formulation-led innovation and acquisitions, and a portfolio that has evolved toward acute care and branded injectable medicines.